BioMarin Pharmaceutical's Achondroplasia Treatment Gets FDA Approval for All Pediatric Patients
21 October 2023 - 7:54AM
Dow Jones News
By Sabela Ojea
BioMarin Pharmaceutical said the Food and Drug Administration
has approved its new drug application to treat all pediatric
patients with a growth condition.
The biotechnology company on Friday said its Voxzogo treatment
is aimed at increasing linear growth and has been approved based on
an improvement in annualized growth velocity.
The medication had previously been indicated for achondroplasia
patients who were 5 years of age and older.
Voxzogo is currently approved in Europe for children with
achondroplasi who are at least 2 years old.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 20, 2023 16:39 ET (20:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Dec 2024 to Jan 2025
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Jan 2024 to Jan 2025
